 | Up a level |
Hauke, I., Neidhardt, G., Engel, C., Schmutzler, R. K. and Hahnen, E. (2016). Performance of prediction programs on clearly pathogenic or neutral BRCA1/2 missense variants from GC-HBOC. Oncol. Res. Treat., 39. S. 3 - 5. BASEL: KARGER. ISSN 2296-5262
Hauke, J., Becker, A., Schnurbein, G., Neidhardt, G., Weber-Lassalle, N., Wappenschmidt, B., Hahnen, E., Meindl, A. and Schmutzler, R. (2014). RAD51C deletion screening identifies a recurrent gross deletion in breast and ovarian cancer families. Oncol. Res. Treat., 37. S. 96 - 97. BASEL: KARGER. ISSN 2296-5262
Heimbach, A., Hauke, J., Richters, L., Kroeber, S., Altmueller, J., Becker, C., Thiele, H., Nuernberg, P., Bluemcke, B., Neidhardt, G., Riehm, K., Schmutzler, R. and Hahnen, E. (2016). TruRisk (R) based next-generation sequencing reveals a high prevalence of deleterious ATM mutations in BRCA1/2-negative breast and ovarian cancer families. Oncol. Res. Treat., 39. S. 52 - 53. BASEL: KARGER. ISSN 2296-5262
Keupp, K., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Larsen, M., Buelow, L., Kroeber, S., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2018). Next-generation sequencing via TruRisk (R) genepanel reveal high mutation prevalence in additional risk genes in German BRCA1/2-negative breast and ovarian cancer families. Eur. J. Hum. Genet., 26. S. 541 - 543. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438
Keupp, K., Richters, L., Buelow, L., Kroeber, S., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2017). TruRisk (R) based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Marme, F., Harter, P., Hauke, J., Heitz, F., Reuss, A., Kommoss, S., Heimbach, A., Prieske, K., Richters, L., Burges, A., Neidhardt, G., de Gregorio, N., El-Balat, A., Hilpert, F., Meier, W., Heubner, M., Kast, K., Braicu, I., Hahnen, E. and Schmutzler, R. (2016). Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). Int. J. Gynecol. Cancer, 26. S. 194 - 196. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438
Neidhardt, G., Hauke, J., Heilmann, S., Hellebrand, H., Surowy, H. M., Klaschik, K., Honisch, E., Gehrig, A., Sutter, C., Rump, A., Bogdanova-Markov, N., Bugert, P., Mangold, E., Steinemann, D., Ramirez, A., Ditsch, N., Arnold, N., Niederacher, D., Burwinkel, B., Thiele, H., Altmueller, I., Nuernberg, P., Engel, C., Wappenschmidt, B., Rhiem, K., Meindl, A., Schmutzler, R. K. and Hahnen, E. (2016). Compelling evidence for FANCM as a breast cancer susceptibility gene. Oncol. Res. Treat., 39. S. 54 - 55. BASEL: KARGER. ISSN 2296-5262
Weber-Lassalle, K., Weber-Lassalle, K., Borde, J., Weber-Lassalle, N., Klaschik, K., Neidhardt, G., Richters, L., Hauke, J., Hahnen, E. and Schmutzler, R. K. (2018). Germline loss-of-function variants in BARD1 are associated with familial breast cancer. Oncol. Res. Treat., 41. S. 3 - 4. BASEL: KARGER. ISSN 2296-5262